A randomized controlled trial of recombinant interferon-beta 1a in Guillain-Barré syndrome.
Autor(es): Pritchard J.; Gray I. A.; Idrissova Z. R.; Lecky B. R. F.; Sutton I. J.; Swan A. V.; Willison H. J.; Winer J. B.; Hughes R. A. C.
Resumo: The authors recruited 19 nonambulant patients with Guillain-Barré syndrome into a pilot, double-blind, randomized, placebo-controlled safety trial of interferon beta 1a (IFN[beta]-1a) (Rebif). Participants received IFN[beta]-1a or placebo subcutaneously three times weekly, 22 microg for the first week and then 44 microg for up to 24 weeks, in addition to IV immunoglobulin (IVIg). IFN[beta] did not have any unexpected interaction with IVIg and there was no significant difference in rate of improvement.
Imprenta: Neurology, v. 61, n. 9, p. 1282-1284, 2003
Identificador do objeto digital: 10.1212/01.WNL.0000092019.53628.88
Descritores: Guillain-Barre Syndrome - Pathogenesis ; Guillain-Barre Syndrome - Proteins ; Guillain-Barre Syndrome - Antibodies ; Guillain-Barre Syndrome - Cytokines ; Guillain-Barre Syndrome - Immunology ; Guillain-Barre Syndrome - Public health
Data de publicação: 2003
